A Study of Zanubrutinib in Patients With ITP

NCT05279872 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia
Bruton Tyrosine Kinase

Interventions

DRUG: Zanubrutinib

Sponsor

Peking University People's Hospital